Ironwood Investment Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating ) by 58.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,506 shares of the company’s stock after selling 3,587 shares during the quarter. Ironwood Investment Management LLC’s holdings in Johnson & Johnson were worth $444,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Family CFO Inc acquired a new position in Johnson & Johnson in the fourth quarter valued at about $26,000. RE Dickinson Investment Advisors LLC raised its stake in shares of Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after buying an additional 98 shares during the last quarter. Professional Financial Advisors LLC boosted its holdings in shares of Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares in the last quarter. Joseph P. Lucia & Associates LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at $38,000. Finally, Advocacy Wealth Management Services LLC raised its holdings in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after buying an additional 67 shares in the last quarter. 68.78% of the shares are owned by hedge funds and other institutional investors.
Johnson & Johnson stock performance
NYSE JNJ opened at $169.31 on Friday. The company’s fifty day moving average is $173.43, and its two hundred day moving average is $174.56. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42, and a quick ratio of 1.17. The firm has a market capitalization of $445.15 billion, a price-to-earnings ratio of 24.64, a P/E/G ratio of 3.17 and a beta of 0.59.
Johnson & Johnson (NYSE:JNJ – Get Rating ) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm’s revenue was up 3.0% year over year. During the same quarter last year, the company earned $2.48 per share. equities research analysts predict that Johnson & Johnson will post 10.05 EPS for the current year.
Johnson & Johnson’s dividend announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents an annual dividend of $4.52 and a yield of 2.67%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.
Insiders place their bets
In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in an SEC filing, which is available at this link. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in an SEC filing, which is available on the SEC’s website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. Disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.
The Wall Street analyst weighs in
JNJ has been the subject of several recent analyst reports. UBS Group dropped their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Wells Fargo & Company boosted their target price on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $189.89.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various products in the field of health care worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com ‘s FREE daily email newsletter.